biote (BTMD) to Release Earnings on Wednesday

Key Points

• biote (NASDAQ: BTMD) is expected to release its Q2 2025 earnings on August 6th, with analysts forecasting earnings of $0.06 per share and revenue of $49.52 million.
• As of the latest trading session, biote shares were down 2.6% to $4.43, with a market capitalization of $242.37 million.
• Major shareholder Guines LLC increased their stake by purchasing 436,037 shares at an average cost of $3.26 per share, boosting their total ownership to over 4.6 million shares.

biote (NASDAQ:BTMD - Get Free Report) is expected to release its Q2 2025 earnings data after the market closes on Wednesday, August 6th. Analysts expect biote to post earnings of $0.06 per share and revenue of $49.52 million for the quarter. biote has set its FY 2025 guidance at EPS.

biote (NASDAQ:BTMD - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.02. biote had a negative return on equity of 19.44% and a net margin of 10.93%. The firm had revenue of $48.99 million for the quarter, compared to the consensus estimate of $47.25 million. On average, analysts expect biote to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

biote Price Performance

Shares of BTMD traded down $0.18 during midday trading on Friday, hitting $3.89. The stock had a trading volume of 120,114 shares, compared to its average volume of 84,602. The company has a 50 day simple moving average of $4.01 and a two-hundred day simple moving average of $4.09. biote has a twelve month low of $3.04 and a twelve month high of $7.34. The firm has a market cap of $212.82 million, a price-to-earnings ratio of 6.38 and a beta of 1.21.

Insider Activity

In other news, major shareholder Guines Llc purchased 436,037 shares of the company's stock in a transaction on Tuesday, May 6th. The shares were purchased at an average price of $3.26 per share, with a total value of $1,421,480.62. Following the purchase, the insider directly owned 4,611,071 shares of the company's stock, valued at $15,032,091.46. This trade represents a 10.44% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 24.00% of the stock is owned by corporate insiders.

Institutional Trading of biote

An institutional investor recently bought a new position in biote stock. AQR Capital Management LLC acquired a new stake in biote Corp. (NASDAQ:BTMD - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 12,871 shares of the company's stock, valued at approximately $43,000. Institutional investors own 21.68% of the company's stock.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.